Acquisition to Enhance StatLab’s European Market Presence and Global Expansion
StatLab Medical Products (“StatLab”), a prominent global entity in the development and manufacturing of medical diagnostic supplies and equipment, has confirmed a binding agreement to purchase Diapath S.p.A, a prominent Italian manufacturer renowned for its histology and cytology products. This strategic acquisition positions StatLab to significantly expand its business operations across Europe and other international markets.
Strengthening Global Market Access
The integration of Diapath, which boasts a comprehensive range of innovative equipment and a strong presence in Europe, Asia-Pacific, the Middle East, Africa, and Latin America, will substantially bolster StatLab’s global market access. Diapath’s product portfolio, including advanced tissue processors, stainers, embedding centers, and microtomes, is distinguished by its Italian design excellence and innovative development processes. This acquisition aligns with StatLab’s objective to broaden its product offerings and enhance its leadership in the global diagnostics sector.
Transaction Details and Leadership Transition
The deal is expected to be finalised in the third quarter of 2024, contingent upon regulatory approvals. Upon completion, Vladimiro Bergamini, founder of Diapath, will assume the role of senior advisor at StatLab. Additionally, Alberto Battistel, Diapath’s Chief Operating Officer, will join StatLab’s executive team as Managing Director of the Diapath business unit, bringing valuable expertise to the integration process.
CEO’s Vision for the Future
Sung-Dae Hong, CEO of StatLab, expressed enthusiasm about the acquisition: “This agreement represents a significant milestone in our strategic plan to offer a comprehensive suite of products supporting the entire anatomic pathology workflow. By incorporating Diapath’s advanced equipment and established market presence, we will enhance our capabilities and expand our reach into global markets, including the U.S. This acquisition will also bolster our European market access for slides, cassettes, and printers, driving innovation and excellence in our product development.”
Diapath’s Innovative Legacy
Diapath, headquartered in Martinengo, near Bergamo, Italy, was established in 1997 by Vladimiro Bergamini. Over the past 27 years, Diapath has evolved from a consumables manufacturer to a leader in the design and production of core histology instruments. The company’s commitment to innovation is evident in its award-winning products, such as the Diapath Donatello automatic tissue processor, which earned a prestigious A’Design Award for Scientific Instruments. The T-Filler Automatic Formalin dispenser, another of Diapath’s innovations, ensures precise formalin ratios while protecting technicians from chemical exposure.
Future Collaboration
Vladimiro Bergamini, CEO and President of Diapath, commented on the merger: “Joining forces with StatLab aligns with our shared vision for growth and innovation. Together, we are poised to elevate the anatomic pathology market through enhanced development and manufacturing capabilities. I am excited about the future collaboration with StatLab to leverage our combined strengths and seize new business opportunities.”
Diapath’s extensive network and expertise will complement StatLab’s global operations, fostering continued advancement and growth in the diagnostic equipment sector.
